Surgical Resection Is Preferred in Selected Solitary Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

Abstract

<b><i>Introduction:</i></b> Sorafenib is the standard care for hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT), though it offers limited survival. This study was designed to compare clinical outcomes between liver resection (surgery) and transarterial chemoembolization plus radiotherapy (TACE-RT) as the initial treatment modality for resectable treatment-naïve solitary HCC combined with subsegmental (Vp1), segmental (Vp2), and lobar (Vp3) PVTT. <b><i>Methods:</i></b> From the institutional HCC registry, we identified 116 patients diagnosed with resectable treatment-naïve HCC with Vp1–Vp3 PVTT based on radiologic images who received surgery (<i>n</i> = 44) or TACE-RT (<i>n</i> = 72) as a primary treatment between 2010 and 2015. A propensity score matching (PSM) model was created. <b><i>Results:</i></b> The TACE-RT group had a higher tumor burden (tumor size, extent, and markers) than the surgery group. Cumulative patient survival curve in the surgery group was significantly higher than that in the TACE-RT group before and after PSM. Liver function was relatively well preserved in the surgery group compared with the TACE-RT group. TACE-RT group, male, increased alkaline phosphatase, and increased platelet count were predisposing factors for patient death in resectable treatment-naïve solitary HCC with PVTT. <b><i>Discussion/Conclusion:</i></b> The present study suggests that surgery is considered as an initial treatment in selectively resectable treatment-naïve solitary HCC with Vp1–Vp3 PVTT.